VHB937
Sponsors
Novartis Pharma AG, Novartis Pharmaceuticals
Conditions
Alzheimer's DiseaseAlzheimer’s diseaseAmyotrophic Lateral Sclerosis (ALS)
Phase 2
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
Active, not recruitingNCT06643481
Start: 2024-10-17End: 2028-07-10Updated: 2026-07-07
A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label
Extension (ASTRALS)
Active, not recruitingCTIS2024-512536-29-00
Start: 2025-02-28Target: 121Updated: 2025-10-23
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RecruitingNCT07094516
Start: 2025-08-07End: 2030-12-31Target: 407Updated: 2026-06-26
A randomized, placebo-controlled, parallel group, 72-week study to evaluate the efficacy and safety of VHB937 in participants with early Alzheimer’s Disease followed by an Extension
Not yet recruitingCTIS2024-516966-12-00
Target: 167Updated: 2026-01-16